

Chapter 150

The Skin and Disorders of the Alimentary Tract, the Hepatobiliary System, the Kidney, and the Cardiopulmonary System

Graham A. Johnston &
Robin A.C. Graham-Brown

REFERENCES

1. Pepin M et al: Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type. *N Engl J Med* **342**(10):673-680, 2000
2. Plomp AS et al: Proposal for updating the pseudoxanthoma elasticum classification system and a review of the clinical findings. *Am J Med Genet A* **152A**(4):1049-1058, 2010
3. Koulaouzidis A, Bhat S, Moschos J: Skin manifestations of liver diseases. *Ann Hepatol* **6**(3):181-184, 2007
4. Murtagh FE et al: Symptoms in advanced renal disease: A cross-sectional survey of symptom prevalence in stage 5 chronic kidney disease managed without dialysis. *J Palliat Med* **10**(6):1266-1276, 2007
5. Vahlquist A, Stenstrom E, Torma H: Vitamin A and beta-carotene concentrations at different depths of the epidermis: A preliminary study in the cow snout. *Ups J Med Sci* **92**(3):253-257, 1987
6. Murakami K et al: Serum levels of 5-s-cysteinyl-dopa are correlated with skin colors in hemodialysis patients but not in peritoneal dialysis patients. *Blood Purif* **28**(3):209-215, 2009
7. Viraben R, Couret B, Gorguet B: Disseminated reticulate hypomelanosis developing during primary biliary cirrhosis. *Dermatology* **195**(4):382-383, 1997
8. Smith KE, Fenske NA: Cutaneous manifestations of alcohol abuse. *J Am Acad Dermatol* **43**(1 Pt 1):1-16; quiz 16-18, 2000
9. Jones EA, Bergasa NV: Evolving concepts of the pathogenesis and treatment of the pruritus of cholestasis. *Can J Gastroenterol* **14**(1):33-40, 2000
10. Jones EA, Neuberger J, Bergasa NV: Opiate antagonist therapy for the pruritus of cholestasis: The avoidance of opioid withdrawal-like reactions. *Q J Med* **95**(8):547-552, 2002
11. Bergasa NV et al: Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: A controlled study. *J Am Acad Dermatol* **41**(3 Pt 1):431-434, 1999
12. Bergasa NV et al: Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial. *Ann Intern Med* **123**(3):161-167, 1995
13. Wolfhagen FH et al: Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. *Gastroenterology* **113**(4):1264-1269, 1997
14. Zein CO, Lindor KD: Latest and emerging therapies for primary biliary cirrhosis and sclerosing cholangitis. *Curr Gastroenterol Rep* **12**(1):13-22, 2010
15. Szepletowski JC, Schwartz RA: Uremic pruritus. *Int J Dermatol* **37**(4):247-253, 1998
16. Stahle-Backdahl M: Uremic pruritus. *Semin Dermatol* **14**(4):297-301, 1995
17. Gilchrist BA et al: Clinical features of pruritus among patients undergoing maintenance hemodialysis. *Arch Dermatol* **118**(3):154-156, 1982
18. Szepletowski JC, Salomon J: Uremic pruritus: Still an important clinical problem. *J Am Acad Dermatol* **51**(5):842-843, 2004
19. Mettang M, Weisshaar E: Pruritus: Control of itch in patients undergoing dialysis. *Skin Therapy Lett* **15**(2):1-5, 2010
20. Gilchrist BA, Rowe JW, Mihm MC Jr: Clinical and histological skin changes in chronic renal failure: Evidence for a dialysis-resistant, transplant-responsive microangiopathy. *Lancet* **2**(8207):1271-1275, 1980
21. Gilchrist BA et al: Relief of uremic pruritus with ultraviolet phototherapy. *N Engl J Med* **297**(3):136-138, 1977

22. Gilcrest BA et al: Ultraviolet phototherapy of uremic pruritus. Long-term results and possible mechanism of action. *Ann Intern Med* **91**(1):17-21, 1979.
23. Schwartz I, Flaina A: Management of uremic pruritus. *Semin Dial* **13**(3):177-180, 2000
24. Kyriazis J, Glotsos J: Dialysate calcium concentration of ≤ 1.25 mmol/l: Is it effective in suppressing uremic pruritus? *Nephron* **84**(1):85-86, 2000
25. De Marchi S et al: Relief of pruritus and decreases in plasma histamine concentrations during erythropoietin therapy in patients with uremia. *N Engl J Med* **326**(15):969-974, 1992
26. Yoshimoto-Furuie K et al: Effects of oral supplementation with evening primrose oil for six weeks on plasma essential fatty acids and uremic skin symptoms in hemodialysis patients. *Nephron* **81**(2):151-159, 1999
27. Szepietowski JC, Reich A, Szepietowski T: Emollients with endocannabinoids in the treatment of uremic pruritus: Discussion of the therapeutic options. *Ther Apher Dial* **9**(3):277-279, 2005
28. Pauli-Magnus C et al: Short-term efficacy of tacrolimus ointment in severe uremic pruritus. *Perit Dial Int* **20**(6):802-803, 2000
29. Johns MK: Skin wrinkling in cystic fibrosis. *Med Biol Illus* **25**(4):205-210, 1975
30. Hill CL et al: Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. *Lancet* **357**(9250):96-100, 2001
31. Sparsa A et al: Routine vs extensive malignancy search for adult dermatomyositis and polymyositis: a study of 40 patients. *Arch Dermatol* **138**(7):885-890, 2002
32. Spiera R, Kagen L: Extramuscular manifestations in idiopathic inflammatory myopathies. *Curr Opin Rheumatol* **10**(6):556-561, 1998
33. Kurzrock R, Cohen PR: Cutaneous paraneoplastic syndromes in solid tumors. *Am J Med* **99**(6):662-671, 1995
34. Rothe MJ, Bialy TL, Grant-Kels JM: Erythroderma. *Dermatol Clin* **18**(3):405-415, 2000
35. Ryan AS, Goldsmith LA: Nutrition and the skin. *Clin Dermatol* **14**(4):389-406, 1996
36. Tosti A. The nail in systemic disease. In: *Diseases of the Nails and Their Management*, edited by R Baran, Dawber R. Oxford, Blackwell Scientific Publications, 1994
37. Terry R: White nails in hepatic cirrhosis. *Lancet* **266**(6815):757-759, 1954
38. Bull RH, Fenton DA, Mortimer PS: Lymphatic function in the yellow nail syndrome. *Br J Dermatol* **134**(2):307-312, 1996
39. Davis MD et al: Natural history of erythromelalgia: Presentation and outcome in 168 patients. *Arch Dermatol* **136**(3):330-336, 2000
40. Cohen JS: Erythromelalgia: New theories and new therapies. *J Am Acad Dermatol* **43**(5 Pt 1):841-847, 2000
41. Davis MD, Rooke T: Erythromelalgia. *Curr Treat Options Cardiovasc Med* **8**(2):153-165, 2006
42. Cohen JS: High-dose oral magnesium treatment of chronic, intractable erythromelalgia. *Ann Pharmacother* **36**(2):255-260, 2002
43. Sandroni P, Davis MD: Combination gel of 1% amitriptyline and 0.5% ketamine to treat refractory erythromelalgia pain: a new treatment option? *Arch Dermatol* **142**(3):283-286, 2006
44. Zyluk A: Scoring system in the assessment of the clinical severity of reflex sympathetic dystrophy of the hand. *Hand Clin* **19**(3):517-521, xi, 2003
45. Zyluk A: The sequelae of reflex sympathetic dystrophy. *J Hand Surg [Br]* **26**(2):151-154, 2001
46. Zyluk A: Complex regional pain syndrome type I. Risk factors, prevention and risk of recurrence. *J Hand Surg [Br]* **29**(4):334-337, 2004
47. Nambu M, Kaneko K, Iijima T: Biochemical and clinical study of muscle atrophy at thenar and hypothenar eminences in patients with cirrhosis. *Liver* **16**(1):19-22, 1996
48. Foutch PG et al: Cutaneous vascular spiders in cirrhotic patients: Correlation with hemorrhage from esophageal varices. *Am J Gastroenterol* **83**(7):723-726, 1988
49. Li CP et al: Role of substance P in the pathogenesis of spider angiomas in patients with nonalcoholic liver cirrhosis. *Am J Gastroenterol* **94**(2):502-507, 1999
50. Li CP et al: Spider angiomas in patients with liver cirrhosis: Role of vascular endothelial growth factor and basic fibroblast growth factor. *World J Gastroenterol* **9**(12):2832-2835, 2003
51. Li CP et al: Spider angiomas in patients with liver cirrhosis: Role of alcoholism and impaired liver function. *Scand J Gastroenterol* **34**(5):520-523, 1999
52. Marinkovich MP: Update on inherited bullous dermatoses. *Dermatol Clin* **17**(3):473-485, vii, 1999
53. Lekas MD, Thayer WR Jr: Dysphagia from benign mucocutaneous pemphigoid. *Ear Nose Throat J* **67**(2):113-116, 1988

54. Abraham SC et al: Esophageal lichen planus: case report and review of the literature. *Am J Surg Pathol* **24**(12):1678-1682, 2000
55. Shimizu H, Tan Kinoshita MT, Suzuki H: Darier's disease with esophageal carcinoma. *Eur J Dermatol* **10**(6):470-472, 2000
56. Pickering MC, Haskard DO: Behcet's syndrome. *J R Coll Physicians Lond* **34**(2):169-177, 2000
57. Howel-Evans W, Clarke CA, Sheppard PM: Carcinoma of the oesophagus with keratosis palmaris et plantaris (tylosis): A study of two families. *Q J Med* **27**(107):413-429, 1958
58. Sjogren RW: Gastrointestinal features of scleroderma. *Curr Opin Rheumatol* **8**(6):569-575, 1996
59. Miric D et al: Dermatological indicators of coronary risk: A case-control study. *Int J Cardiol* **67**(3):251-255, 1998
60. Lotufo PA et al: Male pattern baldness and coronary heart disease: The Physicians' Health Study. *Arch Intern Med* **160**(2):165-171, 2000
61. Norgett EE et al: Recessive mutation in desmoplakin disrupts desmoplakin-intermediate filament interactions and causes dilated cardiomyopathy, woolly hair and keratoderma. *Hum Mol Genet* **9**(18):2761-2766, 2000
62. Rhodes AR et al: Mucocutaneous lentigines, cardiomucocutaneous myxomas, and multiple blue nevi: The "LAMB" syndrome. *J Am Acad Dermatol* **10**(1):72-82, 1984
63. Moder KG, Miller TD, Tazelaar HD: Cardiac involvement in systemic lupus erythematosus. *Mayo Clin Proc* **74**(3):275-284, 1999
64. Marie I et al: Esophageal involvement and pulmonary manifestations in systemic sclerosis. *Arthritis Rheum* **45**(4):346-354, 2001
65. Krafchik BR: Neonatal lupus erythematosus. *Adv Exp Med Biol* **455**:23-26, 1999
66. Steen VD, Medsger TA Jr: Severe organ involvement in systemic sclerosis with diffuse scleroderma. *Arthritis Rheum* **43**(11):2437-2444, 2000
67. Haitjema T et al: Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease): New insights in pathogenesis, complications, and treatment. *Arch Intern Med* **156**(7):714-719, 1996
68. Fried M, Mana F, Urbain D: Cyanosis and cirrhosis of liver: Hepatopulmonary syndrome. *Ned Tijdschr Geneeskde* **144**(37):1790-1793, 2000
69. Alcolado R et al: Systemic arteriovenous malformations: A feature of advanced liver disease. *Gut* **35**(8):1145-1147, 1994
70. Mellor A, Soni N: Fat embolism. *Anaesthesia* **56**(2):145-154, 2001
71. Valencia IC, Colsky A, Berman B: Multicentric reticulohistiocytosis associated with recurrent breast carcinoma. *J Am Acad Dermatol* **39**(5 Pt 2):864-866, 1998
72. Baydur A et al: Respiratory muscle strength, lung function, and dyspnea in patients with sarcoidosis. *Chest* **120**(1):102-108, 2001
73. Baydur A et al: Microscopic pulmonary embolisation of an indwelling central venous catheter with granulomatous inflammatory response. *Eur Respir J* **26**(2):351-353, 2005
74. McCarthy RE III, Kasper EK: A review of the amyloidoses that infiltrate the heart. *Clin Cardiol* **21**(8):547-552, 1998
75. Makol A et al: Lymphomatoid granulomatosis masquerading as interstitial pneumonia in a 66-year-old man: A case report and review of literature. *J Hematol Oncol* **2**:39, 2009
76. Keane MP, Lynch JP III. Pleuropulmonary manifestations of systemic lupus erythematosus. *Thorax* **55**(2):159-166, 2000
77. Veeraraghavan S, Sharma OP: Progressive systemic sclerosis and the lung. *Curr Opin Pulm Med* **4**(5):305-309, 1998
78. Oksuzoglu BC et al: Blue rubber bleb nevus syndrome. *Am J Gastroenterol* **91**(4):780-782, 1996
79. Dinkel HP, Maroske J, Schrod L: Sonographic appearances of the abdominal manifestations of hereditary angioedema. *Pediatr Radiol* **31**(4):296-298, 2001
80. Bork K, Barnstedt SE: Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. *Arch Intern Med* **161**(5):714-718, 2001
81. von und zu Fraunberg M, Kauppinen R: Diagnosis of variegate porphyria—hard to get? *Scand J Clin Lab Invest* **60**(7):605-610, 2000
82. Hartmann K, Henz BM: Mastocytosis: Recent advances in defining the disease. *Br J Dermatol* **144**(4):682-695, 2001
83. Hartmann K, Bruns SB, Henz BM: Mastocytosis: Review of clinical and experimental aspects. *J Invest Dermatol Symp Proc* **6**(2):143-147, 2001
84. Hartmann K, Henz BM: Classification of cutaneous mastocytosis: A modified consensus proposal. *Leuk Res* **26**(5):483-484; author reply 485-486, 2002
85. Hartmann K, Henz BM: Cutaneous mastocytosis – clinical heterogeneity. *Int Arch Allergy Immunol* **127**(2):143-146, 2002

86. Brady RO, Schiffmann R: Clinical features of and recent advances in therapy for Fabry disease. *JAMA* **284**(21):2771-2775, 2000
87. Tizard EJ: Henoch-Schonlein purpura. *Arch Dis Child* **80**(4):380-383, 1999
88. Gunasekaran TS: Henoch-Schonlein purpura: what does the "rash" look like in the gastrointestinal mucosa? *Pediatr Dermatol* **14**(6):437-440, 1997
89. Lankisch MR et al: Acute abdominal pain as a leading symptom for Degos' disease (malignant atrophic papulosis). *Am J Gastroenterol* **94**(4):1098-1099, 1999
90. Harned RK, Buck JL, Sobin LH: The hamartomatous polyposis syndromes: Clinical and radiologic features. *AJR Am J Roentgenol* **164**(3):565-571, 1995
91. Tsao H: Update on familial cancer syndromes and the skin. *J Am Acad Dermatol* **42**(6):939-969; quiz 970-972, 2000
92. Doxey BW, Kuwada SK, Burt RW: Inherited polyposis syndromes: Molecular mechanisms, clinicopathology, and genetic testing. *Clin Gastroenterol Hepatol* **3**(7):633-641, 2005
93. Friedman S et al: Intravenous cyclosporine in refractory pyoderma gangrenosum complicating inflammatory bowel disease. *Inflamm Bowel Dis* **7**(1):1-7, 2001
94. Miller AM et al: Rapid response of severe refractory metastatic Crohn's disease to infliximab. *J Gastroenterol Hepatol* **16**(8):940-942, 2001
95. Bem J, Bradley EL III: Subcutaneous manifestations of severe acute pancreatitis. *Pancreas* **16**(4):551-555, 1998
96. Geary RJ, Long LL, Mutasim DF: Bowel bypass syndrome without bowel bypass. *Cutis* **63**(1):17-20, 1999
97. Steen V: Targeted therapy for systemic sclerosis. *Autoimmun Rev* **5**(2):122-124, 2006
98. Kulke MH, Mayer RJ: Carcinoid tumors. *N Engl J Med* **340**(11):858-868, 1999
99. Kulke M: Advances in the treatment of neuroendocrine tumors. *Curr Treat Options Oncol* **6**(5):397-3409, 2005
100. Usman A et al: Lichenoid eruption following hepatitis B vaccination: First North American case report. *Pediatr Dermatol* **18**(2):123-126, 2001
101. Criado PR et al: Two case reports of cutaneous adverse reactions following hepatitis B vaccine: Lichen planus and granuloma annulare. *J Eur Acad Dermatol Venereol* **18**(5):603-606, 2004
102. Wolf F et al: Generalized granuloma annulare and hepatitis B vaccination. *Eur J Dermatol* **8**(6):435-436, 1998
103. Breitschwerdt B et al: Hepatitis virus-related and ethanol-induced chronic liver disease with or without cryoglobulins—is there a difference concerning clinical or laboratory manifestation? *Infection* **27**(4-5):248-251, 1999
104. Nan DN et al: Atypical skin lesions associated with mixed cryoglobulinaemia and hepatitis C virus infection in a cocaine-consuming patient. *Br J Dermatol* **143**(6):1330-1331, 2000
105. Baleviciene G, Maciuleviciene R, Schwartz RA: Papular acrodermatitis of childhood: the Gianotti-Crosti syndrome. *Cutis* **67**(4):291-294, 2001
106. Tay YK: Gianotti-Crosti syndrome following immunization. *Pediatr Dermatol* **18**(3):262, 2001
107. Tan E et al: Bullous Sweet's syndrome associated with acute hepatitis B infection: a new association. *Br J Dermatol* **143**(4):914-916, 2000
108. Chia SC et al: Pruritus as a presenting symptom of chronic hepatitis C. *Dig Dis Sci* **43**(10):2177-2183, 1998
109. Farkas H et al: Acquired angioedema associated with chronic hepatitis C. *J Allergy Clin Immunol* **103**(4):711-712, 1999
110. Hadziyannis SJ: Skin diseases associated with hepatitis C virus infection. *J Eur Acad Dermatol Venereol* **10**(1):12-21, 1998
111. Carrozzo M, Gandolfo S: Oral diseases possibly associated with hepatitis C virus. *Crit Rev Oral Biol Med* **14**(2):115-127, 2003
112. Beaird LM et al: Incidence of hepatitis C in lichen planus. *J Am Acad Dermatol* **44**(2):311-312, 2001
113. Carrozzo M et al: Increased frequency of HLA-DR6 allele in Italian patients with hepatitis C virus-associated oral lichen planus. *Br J Dermatol* **144**(4):803-808, 2001
114. Carrozzo M et al: Hepatitis C virus-associated oral lichen planus: is the geographical heterogeneity related to HLA-DR6? *J Oral Pathol Med* **34**(4):204-208, 2005
115. Frankel AJ et al: Treatment of psoriasis in patients with hepatitis C: From the Medical Board of the National Psoriasis Foundation. *J Am Acad Dermatol* **61**:1044-1055, 2009
116. Inuzuka M et al: Acquired ichthyosis associated with dermatomyositis in a patient with hepatocellular carcinoma. *Br J Dermatol* **144**(2):416-417, 2001
117. Nasr I et al: Kawasaki disease: an update. *Clin Exp Dermatol* **26**(1):6-12, 2001

118. van Hoek B: The spectrum of liver disease in systemic lupus erythematosus. *Neth J Med* **48**(6):244-253, 1996
119. Islam S, Riordan JW, McDonald JA: Case report: A rare association of primary biliary cirrhosis and systemic lupus erythematosus and review of the literature. *J Gastroenterol Hepatol* **14**(5):431-435, 1999
120. Inagaki H et al: Idiopathic portal hypertension associated with systemic lupus erythematosus. *J Gastroenterol* **35**(3):235-239, 2000
121. Morelli MS, O'Brien FX: Stevens-Johnson Syndrome and cholestatic hepatitis. *Dig Dis Sci* **46**(11):2385-2388, 2001
122. Akimoto S et al: Clinical and immunological characterization of patients with systemic sclerosis overlapping primary biliary cirrhosis: A comparison with patients with systemic sclerosis alone. *J Dermatol* **26**(1):18-22, 1999
123. Graham-Brown RA, Sarkany I, Sherlock S: Lichen planus and primary biliary cirrhosis. *Br J Dermatol* **106**(6):699-703, 1982
124. Sowden JM et al: Isolated lichen planus of the nails associated with primary biliary cirrhosis. *Br J Dermatol* **121**(5):659-662, 1989
125. Oleaga JM et al: Generalized lichen planus associated with primary biliary cirrhosis which resolved after liver transplantation. *Acta Derm Venereol* **75**(1):87, 1995
126. Chu CY et al: Lichen planus with xanthomatous change in a patient with primary biliary cirrhosis. *Br J Dermatol* **142**(2):377-378, 2000
127. Tadros T, Traber DL, Herndon DN: Hepatic blood flow and oxygen consumption after burn and sepsis. *J Trauma* **49**(1):101-108, 2000
128. Tadros T, Traber DL, Herndon DN: Opposite effects of prostacyclin on hepatic blood flow and oxygen consumption after burn and sepsis. *Ann Surg* **239**(1):67-74, 2004
129. Higgins E: Alcohol, smoking and psoriasis. *Clin Exp Dermatol* **25**(2):107-110, 2000
130. Bode S, Gudmand-Hoyer E: Symptoms and hematologic features in consecutive adult coeliac patients. *Scand J Gastroenterol* **31**(1):54-60, 1996
131. Kirby B et al: Abnormal liver function tests induced by dapsone in a patient with dermatitis herpetiformis and primary sclerosing cholangitis. *Br J Dermatol* **141**(1):172-173, 1999
132. Kolbe RE et al: Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. *J Am Acad Dermatol* **60**(5):824-837 2009
133. Zachariae H: Liver biopsies and methotrexate: A time for reconsideration? *J Am Acad Dermatol* **42**(3):531-554, 2000
134. Zachariae H, Sogaard H, Heickendorff L: Serum aminoterminal propeptide of type III procollagen. A non-invasive test for liver fibrogenesis in methotrexate-treated psoriatics. *Acta Derm Venereol* **69**(3):241-244, 1989
135. Zachariae H et al: Serum aminoterminal propeptide of type III procollagen in psoriasis and psoriatic arthritis: Relation to liver fibrosis and arthritis. *J Am Acad Dermatol* **25**(1 Pt 1):50-53, 1991
136. Zachariae H, Heickendorff L, Sogaard H: The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: A 10-year follow-up. *Br J Dermatol* **144**(1):100-103, 2001
137. Zachariae H: Have methotrexate-induced liver fibrosis and cirrhosis become rare? A matter for reappraisal of routine liver biopsies. *Dermatology* **211**(4):307-308, 2005
138. Laharie D et al: Performance of transient elastography for the staging of liver fibrosis: A meta-analysis. *Aliment Pharmacol Ther* **23**(11):1621-1628, 2006
139. Vyas R et al: Use of transient elastography for non-invasive monitoring of methotrexate induced liver fibrosis. Oral Presentation to New Zealand Dermatological Society/Dowling Club, Christchurch, May 2010
140. Friedrich-Rust M et al: Performance of transient elastography for the staging of liver fibrosis: A meta-analysis. *Gastroenterology* **134**(4):960-974, 2008
141. Worth RL: Calciphylaxis: Pathogenesis and therapy. *J Cutan Med Surg* **2**(4):245-248, 1998
142. Hafner J et al: Uremic small-artery disease with medial calcification and intimal hyperplasia (so-called calciphylaxis): A complication of chronic renal failure and benefit from parathyroidectomy. *J Am Acad Dermatol* **33**(6):954-962, 1995
143. Poh-Fitzpatrick MB, Masullo AS, Grossman ME: Porphyria cutanea tarda associated with chronic renal disease and hemodialysis. *Arch Dermatol* **116**(2):191-195, 1980
144. Poh-Fitzpatrick MB, Sosin AE, Bemis J: Porphyrin levels in plasma and erythrocytes of chronic hemodialysis patients. *J Am Acad Dermatol* **7**(1):100-104, 1982
145. Kelly MA, O'Rourke KD: Treatment of porphyria cutanea tarda with phlebotomy in a patient on peritoneal dialysis. *J Am Acad Dermatol* **44**(2 Suppl):336-338, 2001

146. Stevens BR et al: Porphyria cutanea tarda in the setting of renal failure. Response to renal transplantation. *Arch Dermatol* **129**(3):337-339, 1993
147. Sarkell B, Patterson JW: Treatment of porphyria cutanea tarda of end-stage renal disease with erythropoietin. *J Am Acad Dermatol* **29**(3):499-500, 1993
148. Anderson KE et al: Erythropoietin for the treatment of porphyria cutanea tarda in a patient on long-term hemodialysis. *N Engl J Med* **322**(5):315-317, 1990
149. Rapini RP, Herbert AA, Drucker CR: Acquired perforating dermatosis. Evidence for combined transepidermal elimination of both collagen and elastic fibers. *Arch Dermatol* **125**(8):1074-1078, 1989
150. Farrell AM: Acquired perforating dermatosis in renal and diabetic patients. *Lancet* **349**(9056):895-866, 1997
151. Morton CA et al: Acquired perforating dermatosis in a British dialysis population. *Br J Dermatol* **135**(5):671-677, 1996
152. Patterson JW: Progress in the perforating dermatoses. *Arch Dermatol* **125**(8):1121-1123, 1989
153. Haftek M et al: Acquired perforating dermatosis of diabetes mellitus and renal failure: further ultrastructural clues to its pathogenesis. *J Cutan Pathol* **20**(4):350-355, 1993
154. Cowper SE et al: Nephrogenic fibrosing dermopathy. *Am J Dermatopathol* **23**(5):383-393, 2001
155. Cowper SE, Bucala R, LeBoit PE: Case 35-2004: Nephrogenic fibrosing dermopathy. *N Engl J Med*, **352**(16):1723-1724; author reply 1723-1724, 2005
156. Cowper SE et al: Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. *Lancet* **356**(9234):1000-1001, 2000
157. Weinreb JC, Abu-Alfa AK: Gadolinium-based contrast agents and nephrogenic systemic fibrosis: Why did it happen and what have we learned? Gadolinium-based contrast agents and nephrogenic systemic fibrosis: Why did it happen and what have we learned? *J Magn Reson Imaging* **30**(6):1236-1239, 2009
158. Chaudhary K, Wall BM, Raspberry RD: Livedo reticularis: An underutilized diagnostic clue in cholesterol embolization syndrome. *Am J Med Sci* **321**(5):348-351, 2001